BNTX

Biontech SE

Add to Watchlist

Advanced Chart

111.660

+0.31(0.278%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

112.800

Open

112.000

VWAP

111.86

Vol

530.28K

Mkt Cap

26.84B

Low

111.060

Amount

59.32M

EV/EBITDA(TTM)

Total Shares

240.99M

10.62B

EV/OCF(TTM)

P/S(TTM)

7.93

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

931.05M

-25.21%

-0.183

-122.6%

938.82M

-21.11%

-0.871

-180.65%

265.64M

+45.32%

-1.853

+7.08%

Estimates Revision

The market is revising Upward the revenue expectations for BioNTech SE (BNTX) for FY2025, with the revenue forecasts being adjusted by 9.01% over the past three months. During the same period, the stock price has changed by 14.79%.

Revenue Estimates for FY2025

Revise Upward

+9.01%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-36.3%

In Past 3 Month

Stock Price

Go Up

+14.79%

In Past 3 Month

19 Analyst Rating

25.35% Upside

Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 139.97 USD with a low forecast of 108.49 USD and a high forecast of 185.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

5 Hold

0 Sell

Moderate Buy

25.35% Upside

Current: 111.660

Low

108.49

Averages

139.97

High

185.00

25.35% Upside

Current: 111.660

Low

108.49

Averages

139.97

High

185.00

Wells Fargo

Mohit Bansal

Overweight

downgrade

$170 -> $150

2025-08-05

Reason

Wells Fargo

Mohit Bansal

Price Target

$170 -> $150

2025-08-05

downgrade

Overweight

Reason

Wells Fargo analyst Mohit Bansal lowered the firm's price target on BioNTech (BNTX) to $150 from $170 to reflect Bristol Myers (BMY), while keeping an Overweight rating on the shares. The firm notes several oncology updates are expected this year, including BNT327 dose optimization data gating Phase 3 starts and first adjuvant setting readout for the personalized cancer vaccine.

BofA

Buy

maintain

$126 -> $134

2025-08-04

Reason

BofA

Price Target

$126 -> $134

2025-08-04

maintain

Buy

Reason

BofA raised the firm's price target on BioNTech to $134 from $126 and keeps a Buy rating on the shares. The company's Q2 results saw revenue well ahead of consensus expectations, with the firm also noting that its COVID revenues provide runway for further pipeline execution, the analyst tells investors in a research note. BioNTech also remains committed to maintaining differentiation through variant-adapted boosters and combo vaccine development, BofA added.

Clear Street

Buy

maintain

$181 -> $185

2025-08-04

Reason

Clear Street

Price Target

$181 -> $185

2025-08-04

maintain

Buy

Reason

Clear Street raised the firm's price target on BioNTech to $185 from $181 and keeps a Buy rating on the shares after updating the firm's model to a year-end 2026 valuation following the company reporting Q2 results this morning. The company remains on track to report Phase 2 dose optimization results from BNT327 studies in small cell lung cancer and triple negative breast cancer in the second half of 2025, notes the analyst, who calls the company's oncology pipeline "underappreciated."

BofA

Buy

downgrade

$127 -> $126

2025-07-16

Reason

BofA

Price Target

$127 -> $126

2025-07-16

downgrade

Buy

Reason

BofA lowered the firm's price target on BioNTech to $126 from $127 and keeps a Buy rating on the shares. BofA remains cautious on the near-term outlook for the COVID-19 franchise and will look for updates in Q2 call and additional color on policy and guideline impacts, the analyst tells investors in a research note.

Morgan Stanley

Terence Flynn

Overweight

maintain

$132 -> $133

2025-07-10

Reason

Morgan Stanley

Terence Flynn

Price Target

$132 -> $133

2025-07-10

maintain

Overweight

Reason

Morgan Stanley analyst Terence Flynn raised the firm's price target on BioNTech to $133 from $132 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.

H.C. Wainwright

Buy

downgrade

$145 -> $138

2025-06-17

Reason

H.C. Wainwright

Price Target

$145 -> $138

2025-06-17

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on BioNTech (BNTX) to $138 from $145 and keeps a Buy rating on the shares after the company entered into a definitive purchase agreement with CureVac (CVAC). The firm views the acquisition as "incrementally positive," saying removes a litigation headwind for BioNTech, strengthens the company's mRNA patent portfolio, and expands BioNTech's manufacturing capability.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Biontech SE (BNTX.O) is -19.08, compared to its 5-year average forward P/E of -3.88. For a more detailed relative valuation and DCF analysis to assess Biontech SE 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.88

Current PE

-19.08

Overvalued PE

5.61

Undervalued PE

-13.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

3.79

Current EV/EBITDA

-7.02

Overvalued EV/EBITDA

13.32

Undervalued EV/EBITDA

-5.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

5.70

Current PS

9.70

Overvalued PS

8.40

Undervalued PS

3.00